• The Journal of the Korean bone and joint tumor society
• /
• v.12 no.2
• /
• pp.155-160
• /
• 2006

Giant cell-rich osteosarcoma is a rare tumor that is hard to distinguish from giant cell tumors of bone. The location and radiographic aspect of these tumors can be identical. The histologic differentiation between a giant cell-rich osteosarcoma and a giant cell tumor can be difficult. Due to the different prognosis and treatment strategies of these tumors it is essential to make the right diagnosis at presentation. This article reports a case of a giant cell-rich osteosarcoma of the proximal tibia that initially was diagnosed histologically as a giant cell tumor by needle biopsy.

• The Journal of the Korean bone and joint tumor society
• /
• v.5 no.3
• /
• pp.169-177
• /
• 1999

Osteosarcoma in patients older than 40 years are rare, however they have different clinical, radiological and pathological features from those of younger patients. Sometimes accurate histologic diagnosis is not easy, which is important in determining the correct surgical treatment and appropriate chemotherapy. Since January 1995, 11 patients with osteosarcoma occurring in patients older than 40 years have been diagnosed, treated and followed up for more than 6 months. In contrast to osteosarcoma in children and adolescents, only 4 cases(36.4%) were conventional types, while the others included 2 malignant fibrous histiocytoma-like types, 2 small cell types, 2 periosteal osteosarcomas and 1 giant cell-rich type. Seven cases showed purely osteolytic or predominantly osteolytic bony lesions and 8 were in Enneking stage IIB. Performed surgical treatments included 2 amputations, 6 wide resections and reconstructions, and one curettage and autogenous bone graft. In the remaining 2 cases, definitive surgical treatments included not carried out because of old age, multifocal involvement or poor medical tolerance. Neoadjuvant and adjuvant chemotherapies were performed in 9 of 11 patients. At last follow-up, there were 6 continuously disease-free survivals, 3 alive with diseases and 2 died of diseases. The overall cumulative 4-year survival rate calculated using Kaplan-Meier's productlimit method was 59.3%. For improved oncologic outcomes and survivals, early and accurate diagnosis, surgical treatment with adequate margin and neoadjuvant and adjuvant chemotherapy will be necessary.